TABLE 1.
Characteristics of the study participants included in the intention-to-treat analysis
| Treated group# (n=1298) | Untreated control group (n=1151) | p-value | |
| Age (years) | |||
| 50–55 | 317 (24.42) | 264 (22.94) | 0.637 |
| 56–60 | 343 (26.43) | 295 (25.63) | |
| 61–65 | 333 (25.65) | 299 (25.98) | |
| 66–70 | 305 (23.50) | 293 (25.46) | |
| Gender | |||
| Female | 590 (45.45) | 512 (44.48) | 0.630 |
| Male | 708 (54.55) | 639 (55.52) | |
| BMI (kg·m−2) | |||
| <18.5 | 542 (41.76) | 471 (40.92) | 0.755 |
| 18.5– <24 | 30 (2.31) | 22 (1.91) | |
| 24– <28 | 493 (37.98) | 458 (39.79) | |
| ≥28 | 233 (17.95) | 200 (17.38) | |
| Smoking | |||
| Never-smoker | 765 (58.94) | 691 (60.03) | 0.581 |
| Ever-smoker | 533 (41.06) | 460 (39.97) | |
| Presence of TB history | |||
| No | 1284 (98.92) | 1124 (97.65) | 0.015* |
| Yes | 14 (1.08) | 27 (2.35) | |
| Alcohol drinking | |||
| No | 901 (69.41) | 810 (70.37) | 0.606 |
| Yes | 397 (30.59) | 341 (29.63) | |
| Fasting blood glucose (mmol·L−1) | |||
| ≤7 | 1211 (93.30) | 1049 (91.14) | 0.046* |
| >7 | 87 (6.70) | 102 (8.86) | |
| History of silicosis | |||
| No | 1270 (97.84) | 1127 (97.91) | 0.902 |
| Yes | 28 (2.16) | 24 (2.09) |
Data are presented as n (%), unless otherwise stated. BMI: body mass index; TB: tuberculosis. #: completed 6 weeks of twice-weekly rifapentine plus isoniazid (both with a maximum dose of 600 mg). p-value by Chi-squared test. *: p<0.05.